Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Director · CEO | July 01, 2021 | July 02, 2021 |
| ZyVersa Therapeutics, Inc.ZVSA · Entity 8639 | Director | July 11, 2025 | July 15, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TherapeuticsMD, Inc.
Report date July 01, 2021 · Filed July 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,493,333 |
Reported balance
After 2021-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-01 · Grant · Acquired 1,493,333 · Balance 1,493,333 F1: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 746,667 |
Reported balance
After 2021-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-07-01 · Grant · Acquired 746,667 · Balance 746,667 F2: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: One half of the performance stock units (PSUs) vest based on the issuer achieving certain revenue milestones over the period from 2021 through 2023, and one half of the PSUs vest based on the issuer achieving certain earnings before interest, taxes, depreciation and amortization (EBITDA) milestones no later than December 31, 2023. In the event that any of the foregoing are not achieved, the corresponding portion of the PSUs will be forfeited. The number of PSUs listed is the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. In accordance with the terms of the issuer's 2019 Stock Incentive Plan, no PSUs will vest prior to the one-year anniversary of the grant date. Each PSU represents a contingent right to receive one share of common stock of the issuer.
F2: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning July 1, 2022, becoming fully vested on July 1, 2024.
ZyVersa Therapeutics, Inc.
Report date July 11, 2025 · Filed July 15, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2035-07-11 | Direct | 11,066 |
Reported balance
After 2025-07-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-11 · Grant · Acquired 11,066 · Balance 11,066 F1: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on July 11, 2025, and vest and become exercisable in equal annual installments on the first three anniversaries of the grant date, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 12, 2018 Filed Nov 15, 2018 01:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 92,000 | $4.73 | $435,160.00 |
DisclosureSEC source: 0001387131-18-006220 · finizio-form4_111218.xml · nonDerivative · entry 2 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,393,559 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.63 to $4.87, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2018 Filed Nov 15, 2018 01:02 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 92,000 | $0.10 | $9,365.60 |
DisclosureSEC source: 0001387131-18-006220 · finizio-form4_111218.xml · nonDerivative · entry 1 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,485,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2018 Filed Oct 30, 2018 01:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-005729 · finizio-form4_102518.xml · derivative · entry 8 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 736,910 Underlying: Common Stock · 92,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2018 Filed Oct 30, 2018 01:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 92,000 | $5.12 | $470,764.00 |
DisclosureSEC source: 0001387131-18-005729 · finizio-form4_102518.xml · nonDerivative · entry 4 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,393,559 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.0 to $5.42, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 26, 2018 Filed Oct 30, 2018 01:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 92,000 | $0.10 | $9,365.60 |
DisclosureSEC source: 0001387131-18-005729 · finizio-form4_102518.xml · nonDerivative · entry 3 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,485,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2018 Filed Oct 30, 2018 01:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-005729 · finizio-form4_102518.xml · derivative · entry 7 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 828,910 Underlying: Common Stock · 92,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2018 Filed Oct 30, 2018 01:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 92,000 | $5.45 | $501,308.00 |
DisclosureSEC source: 0001387131-18-005729 · finizio-form4_102518.xml · nonDerivative · entry 2 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,393,559 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.55, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 25, 2018 Filed Oct 30, 2018 01:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 92,000 | $0.10 | $9,365.60 |
DisclosureSEC source: 0001387131-18-005729 · finizio-form4_102518.xml · nonDerivative · entry 1 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,485,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2018 Filed Oct 15, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-005451 · finizio-form4_101118.xml · derivative · entry 8 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920,910 Underlying: Common Stock · 92,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2018 Filed Oct 15, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 92,000 | $5.45 | $501,216.00 |
DisclosureSEC source: 0001387131-18-005451 · finizio-form4_101118.xml · nonDerivative · entry 4 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,393,559 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.37 to $5.67, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 12, 2018 Filed Oct 15, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 92,000 | $0.10 | $9,365.60 |
DisclosureSEC source: 0001387131-18-005451 · finizio-form4_101118.xml · nonDerivative · entry 3 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,485,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2018 Filed Oct 15, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-005451 · finizio-form4_101118.xml · derivative · entry 7 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012,910 Underlying: Common Stock · 92,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 11, 2018 Filed Oct 15, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 92,000 | $5.65 | $519,616.00 |
DisclosureSEC source: 0001387131-18-005451 · finizio-form4_101118.xml · nonDerivative · entry 2 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,393,559 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.4 to $5.75, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 11, 2018 Filed Oct 15, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 92,000 | $0.10 | $9,365.60 |
DisclosureSEC source: 0001387131-18-005451 · finizio-form4_101118.xml · nonDerivative · entry 1 Finizio Robert G · CIK 0001532235 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,485,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-004940 · finizio-form4_092018.xml · derivative · entry 8 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,104,910 Underlying: Common Stock · 92,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 92,000 | $6.67 | $613,640.00 |
DisclosureSEC source: 0001387131-18-004940 · finizio-form4_092018.xml · nonDerivative · entry 4 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,393,559 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.92, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 21, 2018 Filed Sep 24, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 92,000 | $0.10 | $9,365.60 |
DisclosureSEC source: 0001387131-18-004940 · finizio-form4_092018.xml · nonDerivative · entry 3 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,485,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2018 Filed Sep 24, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-004940 · finizio-form4_092018.xml · derivative · entry 7 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,196,910 Underlying: Common Stock · 92,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2018 Filed Sep 24, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 92,000 | $6.58 | $605,360.00 |
DisclosureSEC source: 0001387131-18-004940 · finizio-form4_092018.xml · nonDerivative · entry 2 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,393,559 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.32 to $6.755, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2018 Filed Sep 24, 2018 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 92,000 | $0.10 | $9,365.60 |
DisclosureSEC source: 0001387131-18-004940 · finizio-form4_092018.xml · nonDerivative · entry 1 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,485,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 23:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-004627 · finizio-form4_090618.xml · derivative · entry 8 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,288,910 Underlying: Common Stock · 92,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 23:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 92,000 | $6.22 | $572,240.00 |
DisclosureSEC source: 0001387131-18-004627 · finizio-form4_090618.xml · nonDerivative · entry 4 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,393,559 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.095 to $6.31, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 07, 2018 Filed Sep 10, 2018 23:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 92,000 | $0.10 | $9,365.60 |
DisclosureSEC source: 0001387131-18-004627 · finizio-form4_090618.xml · nonDerivative · entry 3 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,485,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 23:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001387131-18-004627 · finizio-form4_090618.xml · derivative · entry 7 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,380,910 Underlying: Common Stock · 92,000 shares Expires 2019-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 23:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | SaleCommon Stock | 92,000 | $6.25 | $575,000.00 |
DisclosureSEC source: 0001387131-18-004627 · finizio-form4_090618.xml · nonDerivative · entry 2 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,393,559 F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.145 to $6.385, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 23:00 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 92,000 | $0.10 | $9,365.60 |
DisclosureSEC source: 0001387131-18-004627 · finizio-form4_090618.xml · nonDerivative · entry 1 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,485,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 21:50 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 440,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001387131-18-001129 · finizio-form4_031518.xml · derivative · entry 1 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 440,000 Underlying: Common Stock · 440,000 shares Expires 2028-03-15 F1 · derivative.exercise_date: Underlying shares vest as follows: 146,667 shares on the first anniversary date of the grant, 146,667 shares on the second anniversary date of the grant, and 146,666 shares on the third anniversary date of the grant. Read SEC document |
| December 01, 2017 Filed Feb 13, 2018 02:17 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GiftCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-18-000565 · finizio-form5_123117.xml · nonDerivative · entry 1 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,393,559 Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 22:31 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-qualified stock option (right to buy) · Derivative | 445,000 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001387131-17-001456 · finizio-form4_031517.xml · derivative · entry 1 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,000 Underlying: Common Stock · 445,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: Underlying shares vest as follows: 148,333 shares on the first anniversary date of the grant, 148,333 shares on the second anniversary date of the grant, and 148,334 shares on the third anniversary date of the grant. Read SEC document |
| December 30, 2016 Filed Feb 14, 2017 22:55 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GiftCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-17-000843 · robert_finizio-form5.xml · nonDerivative · entry 2 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,643,559 Read SEC document |
| December 29, 2016 Filed Feb 14, 2017 22:55 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GiftCommon Stock | 165,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001387131-17-000843 · robert_finizio-form5.xml · nonDerivative · entry 1 Finizio Robert G · CIK 0001532235 · Director · CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,651,059 F1 · balance_after: Includes 20,000 shares of Common Stock that were inadvertently reported as being disposed of by gift on the Reporting Person's Form 5 filed with the SEC on February 16, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.